# Space Exploration Technologies Corp: financial statements, quarterly

SPCX · Nasdaq · CIK 1181412 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/spcx.md) · [Financials](/companies/spcx/financials.md) · [Filings](/companies/spcx/filings.md) · [Insiders](/companies/spcx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/spcx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-06-30) | period not labelled (2025-09-30) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $bn | [4.1](/filings/0001628280-26-052535.md) | [5.6](/filings/0001628280-26-066880.md) | [7.8](/filings/0001628280-26-052535.md) | [14.6](/filings/0001628280-26-066880.md) |
| Cost of revenue | $bn | [2.3](/filings/0001628280-26-052535.md) | [2.7](/filings/0001628280-26-066880.md) | [3.5](/filings/0001628280-26-052535.md) | [5.5](/filings/0001628280-26-066880.md) |
| Research and development | $bn | [2.0](/filings/0001628280-26-052535.md) | [2.3](/filings/0001628280-26-066880.md) | [3.5](/filings/0001628280-26-052535.md) | [4.6](/filings/0001628280-26-066880.md) |
| Selling, general and administrative | $bn | [0.6](/filings/0001628280-26-052535.md) | [0.6](/filings/0001628280-26-066880.md) | [0.9](/filings/0001628280-26-052535.md) | [1.7](/filings/0001628280-26-066880.md) |
| Operating income | $bn | [(1.0)](/filings/0001628280-26-052535.md) | [(0.3)](/filings/0001628280-26-066880.md) | [(0.1)](/filings/0001628280-26-052535.md) | [2.8](/filings/0001628280-26-066880.md) |
| Interest expense | $bn | [0.4](/filings/0001628280-26-052535.md) | [0.5](/filings/0001628280-26-066880.md) | [0.6](/filings/0001628280-26-052535.md) | [0.7](/filings/0001628280-26-066880.md) |
| Income tax | $bn | [0.1](/filings/0001628280-26-052535.md) | [0.6](/filings/0001628280-26-066880.md) | [0.0](/filings/0001628280-26-052535.md) | [(0.4)](/filings/0001628280-26-066880.md) |
| Net income | $bn | [(1.0)](/filings/0001628280-26-052535.md) | [(1.1)](/filings/0001628280-26-066880.md) | [(0.5)](/filings/0001628280-26-052535.md) | [4.4](/filings/0001628280-26-066880.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0001628280-26-052535.md) | [(0.36)](/filings/0001628280-26-066880.md) | [(0.09)](/filings/0001628280-26-052535.md) | [0.35](/filings/0001628280-26-066880.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0001628280-26-052535.md) | [(0.36)](/filings/0001628280-26-066880.md) | [(0.09)](/filings/0001628280-26-052535.md) | [0.37](/filings/0001628280-26-066880.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-09-30) | period not labelled (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | [24.7](/filings/0001628280-26-066880.md) | not reported | [93.5](/filings/0001628280-26-052535.md) | [51.3](/filings/0001628280-26-066880.md) |
| Current assets | $bn | not reported | not reported | not reported | not reported | [31.0](/filings/0001628280-26-066880.md) | not reported | [108](/filings/0001628280-26-052535.md) | [101](/filings/0001628280-26-066880.md) |
| Total assets | $bn | not reported | not reported | not reported | not reported | [92.1](/filings/0001628280-26-066880.md) | not reported | [193](/filings/0001628280-26-052535.md) | [254](/filings/0001628280-26-066880.md) |
| Current liabilities | $bn | not reported | not reported | not reported | not reported | [21.4](/filings/0001628280-26-066880.md) | not reported | [21.1](/filings/0001628280-26-052535.md) | [32.7](/filings/0001628280-26-066880.md) |
| Total liabilities | $bn | not reported | not reported | not reported | not reported | [50.8](/filings/0001628280-26-066880.md) | not reported | [65.5](/filings/0001628280-26-052535.md) | [77.3](/filings/0001628280-26-066880.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | [21.7](/filings/0001628280-26-066880.md) | not reported | [38.3](/filings/0001628280-26-052535.md) | [37.9](/filings/0001628280-26-066880.md) |
| Shareholders' equity | $bn | [4.9](/filings/0001628280-26-066880.md) | [5.3](/filings/0001628280-26-052535.md) | [5.2](/filings/0001628280-26-066880.md) | [4.7](/filings/0001628280-26-066880.md) | [2.6](/filings/0001628280-26-066880.md) | [34.5](/filings/0001628280-26-052535.md) | [127](/filings/0001628280-26-066880.md) | [177](/filings/0001628280-26-066880.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-09-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: |
| Operating cash flow | $bn | [3.8 d](/filings/0001628280-26-066880.md) | [9.6 d](/filings/0001628280-26-066880.md) |
| Capital expenditure | $bn | [6.9 d](/filings/0001628280-26-066880.md) | [19.6 d](/filings/0001628280-26-066880.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-06-30) | period not labelled (2025-09-30) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | billions of shares | [2.9](/filings/0001628280-26-052535.md) | [2.9](/filings/0001628280-26-066880.md) | [5.9](/filings/0001628280-26-052535.md) | [12.5](/filings/0001628280-26-066880.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.